)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Standard BioTools
Standard BioTools (LAB) investor relations material
Standard BioTools Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 revenue was $19.4M, down 1% YoY; gross margin improved to 55.9% from 48.5%, while continuing operations recorded a $15.0M net loss. A $30.0M Illumina-related gain drove total net income to $13.5M.
Strategic transition advanced through the planned Treeline merger and sales of the mass cytometry and microfluidics businesses.
Financial highlights
Q3 product revenue rose 4% YoY to $14.3M: instruments increased 18% to $6.0M, while consumables declined 4% to $8.3M; services and other revenue fell 12% to $5.1M.
Nine-month revenue was $60.6M, down 1% YoY; gross profit rose 5% to $32.7M, with gross margin at 53.9% versus 50.6%.
Q3 operating expenses fell 28% to $30.6M; continuing-operations net loss narrowed to $15.0M from $31.7M.
Nine-month total net income was $113.8M versus a $94.2M loss, including $164.9M income from discontinued operations.
Outlook and guidance
Merger with Treeline was expected to close in Q4 2026, subject to customary conditions and stockholder approval; the stockholder meeting was scheduled for November 19, 2026.
Existing liquidity and capital sources were expected to support operations for at least 12 months from the filing date.
Consumables are expected to remain a substantial portion of revenue and grow over time through higher utilization, a larger installed base, and new offerings.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Standard BioTools
- Q2 2026 revenue fell 8% year-over-year, but gross margin rose to 52.4% and EBITDA loss narrowed.LAB
Q2 2026 - All proposals passed, including director elections and equity plan approvals, with no Q&A.LABAGM 2026
- All-stock merger forms a $900M+ cash biopharma with a deep pipeline and new leadership.LABM&A announcement
- Q1 2026 revenue grew 5% to $21.1M, with net income surging on a major asset sale.LABQ1 2026
- 2026 meeting features director elections, key compensation votes, and new equity plan approval.LABProxy filing
- Key votes include director elections, executive pay, auditor ratification, and equity plan changes.LABProxy filing
- Q3 2024 revenue was $45M, with improved margins and accelerated merger synergies.LABQ3 2024
- Q1 2025 revenue fell 10% to $40.8M, but cost cuts and improved margins narrowed losses.LABQ1 2025
- Cost synergies and consumables growth offset revenue declines, supporting a strong 2025 outlook.LABQ4 2024
Next Standard BioTools earnings date
Q4 202610 Feb, 2027
Standard BioTools
Next Standard BioTools earnings date
Q4 202610 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Standard BioTools Inc. (formerly known as Fluidigm Corporation) is a life sciences technology company that provides advanced tools and systems for biological research. The company specializes in products for mass cytometry, genomics, and other high-throughput techniques that enable researchers to study cell behavior, gene expression, and protein interactions at the molecular level. Standard BioTools' solutions support research in areas such as cancer, immunology, and drug discovery. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.